发明名称 CANCER COMBINATION THERAPY COMPRISING AZD2171 AND ZD1839.
摘要 <p>The present invention elates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with ZD1839; to a pharmaceutical composition comprising AZD2171 and ZD1839; to a combination product comprising AZD2171 and ZD1839 for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and ZD1839; to the use of AZD2171 and ZD1839 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.</p>
申请公布号 MXPA06000412(A) 申请公布日期 2006.03.17
申请号 MX2006PA00412 申请日期 2004.07.08
申请人 ASTRAZENECA AB 发明人 STEPHEN ROBERT WEDGE
分类号 A61K31/517;A61K41/00;A61P35/00;(IPC1-7):A61K31/517 主分类号 A61K31/517
代理机构 代理人
主权项
地址